Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7310245 | 0.84 | CYP11B1 (0.34) | CYP11B1CYP11B2KMT2AMEN1CYP1A2 | |
| SCHEMBL9585649 | 0.84 | TAAR1 (0.35) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL6743058 | 0.81 | CYP11B1 (0.33) | CYP11B1CYP11B2KMT2AMEN1CYP1A2 | |
| SCHEMBL7274096 | 0.81 | MEN1 (0.37) | CYP11B1CYP11B2KMT2AMEN1KCNN4 | |
| SCHEMBL10457156 | 0.80 | P2RX3 (0.36) | CYP11B1CYP11B2KMT2AMEN1LMNA | |
| SCHEMBL6667217 | 0.79 | CYP11B1 (0.37) | CYP11B1CYP11B2MAPTTSHRRAB9A | |
| SCHEMBL7273914 | 0.78 | ADRA2C (0.35) | CYP11B1CYP11B2ADRB2ADRB1CYP2D6 | |
| SCHEMBL6662261 | 0.78 | KDM4E (0.34) | CYP11B1CYP11B2TSHRTBXAS1RAB9A | |
| SCHEMBL10439558 | 0.78 | CYP1A2 (0.44) | CYP11B1CYP11B2KMT2AMEN1SLC22A1 | |
| SCHEMBL1003836 | 0.77 | CYP11B1 (0.34) | CYP11B1CYP11B2KMT2AMEN1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| EP-2014291-B1 | Piperazinone compounds as anti-tumor and anti-cancer agents | UNIV YALE (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| US-7763620-B2 | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | YALE UNIVERSITY (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1427418-B1 | PIPERAZINONE COMPOUNDS AS ANTI-TUMOR AND ANTI-CANCER AGENTS | UNIV YALE (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2094668-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-7501436-B2 | 5-HT3 receptor antagonists and methods of use | ARYX THERAPEUTICS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-2014291-A2 | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | YALE UNIVERSITY (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-0353983-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1990-02-07 | — | — | EP | disclosed |
| EP-0339959-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-11-02 | — | — | EP | disclosed |
| EP-0336759-A1 | Imidazole derivatives | GLAXO GROUP LIMITED (GB) | 1989-10-11 | — | — | EP | disclosed |
| US-4859662-A | Tetrahydro-imidazolylmethylcarbazolones and analogs thereof for treating 5-HT function disturbances | GLAXO GROUP LIMITED (GB) | 1989-08-22 | — | — | US | disclosed |
| US-4822881-A | PSYCHOTIC DISORDERS, ANXIETY, NAUSEA, VOMITING | GLAXO GROUP LIMITED | 1989-04-18 | — | — | US | disclosed |
| EP-0306323-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-03-08 | — | — | EP | disclosed |
| US-4808581-A | ANXIOLYTIC, ANTIEMETIC, TREATMENT OF PSYCHOLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1989-02-28 | — | — | US | disclosed |
| US-4738979-A | ADRENERGIC RECEPTORS; ANTI-CONVULSIVE DRUG; TREATMENT OF METABOLIC AND NEUTRAL DISORDERS | G. D. SEARLE & CO. (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0242973-A1 | Indole derivatives, method for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1987-10-28 | — | — | EP | disclosed |
| EP-0194984-A1 | Derivatives of imidazole, their preparation and utilisation, and pharmaceutical compositions containing these derivatives | CONTINENTAL PHARMA, INC. (BE) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | CYP11B1 540/4885CYP11B2 522/4885KMT2A 1992/4885 |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | CYP11B1 540/4885CYP11B2 522/4885KMT2A 1992/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | CYP11B1 4653/4885CYP11B2 4477/4885KMT2A 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.